Eli Lilly to offer half-priced versions of two more insulin products

Eli Lilly and Co reported on Tuesday it plans to sell two versions of insulin products at half their current U.S. list prices, 8 months after it started selling a half-priced version of its widely-used insulin lispro recombinant (Humalog) injection.

Eli Lilly and Co reported on Tuesday it plans to sell two versions of insulin products at half their current U.S. list prices, 8 months after it started selling a half-priced version of its widely-used insulin lispro recombinant (Humalog) injection. Lilly will sell new versions of the insulin products at a list price of $265.20 for a pack of five KwikPens. They will be available at that price by mid-April, the company said. Major insulin makers Lilly, Sanofi, and Novo Nordisk have been making some of their life-sustaining diabetes medicine available at lower costs. "Insurance coverage should ensure no one with diabetes is forced to ration or skip doses for financial reasons," Lilly diabetes head Mike Mason said in a statement on Tuesday.